Astellas Pharma, Inc.’s Veozah (fezolinetant) for hot flashes caused by menopause got off to a slow commercial start, despite a high unmet need for nonhormonal treatment options for menopausal women. A new updated warning from the US Food and Drug Administration on a rare but serious risk of liver injury could further complicate the commercial ramp.
Veozah Warning On Liver Injury Could Present New Commercial Roadblock
The US FDA updated labeling for Astellas’ drug for hot flashes after a postmarketing report of a single patient with signs and symptoms of liver injury taking the medicine.
